Idarubicin (IDA) is the analog of daunorubicin (DNR). The absence of the methoxy group at position 4 of IDA remarkably improved lipophilicity, which is responsible for extra cellular uptake, higher DNA-binding ability, and considerable cytotoxicity in correlation with doxorubicin (DOX) and DNR. In this paper, we conceived two principal objectives: we realized the crystal structure of IDA by X-ray diffraction measurements on single crystals at room temperature (monoclinic, space group 2, = 5.1302(2) Å, = 9.9122(5) Å, = 24.8868(11) Å; β = 91.425(4)°; = 1265.14(10) Å) with refinements of the structure converged to the final = 3.87%. The second objective has been to develop gold nanoparticles encapsulated with idarubicin through an original methodology in which gold salt (HAuCl) is chelated with IDA and diacid polymer (PEG) to form hybrid nanoparticles called IDA IN PEG-AuNPs in which drug solubility was enhanced. The computational studies were in agreement with the experimental observations. These hybrid nanoparticles and their precursors were analyzed by Raman, UV-Vis, H NMR, and transmission electron microscopy (TEM). The main results are completed by a theoretical approach to understand the whole process.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818310PMC
http://dx.doi.org/10.1021/acsomega.0c04501DOI Listing

Publication Analysis

Top Keywords

gold nanoparticles
8
hybrid nanoparticles
8
ida
5
idarubicin-gold complex
4
complex crystal
4
crystal growth
4
growth gold
4
nanoparticles
4
nanoparticles idarubicin
4
idarubicin ida
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!